

Supplementary Table 1 - Distribution of NCI CTCAE Severity grades and corresponding mean EORTC QLQ-CIPN20 scores in the study population.

Grades by NCI-CTCAE	N (%)	Mean (SD)
Grade 1	13 (12)	32.77 (2.05)
Grade 2	85 (79)	44.09 (4.8)
Grade 3 & 4	10 (9)	57.23 (0.8)
Total	108 (100)	43.9 (19.33)

NCI CTCAE - National Cancer Institute Common Terminology Criteria for Adverse Events, EORTC QLQ-CIPN20 - European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire–Chemotherapy-Induced Peripheral Neuropathy 20-item scale, SD – Standard deviation.

Supplementary Table 2 – Regrouping of Variables for Multivariate Regression Analysis

Groups	Regrouping category	N (%)
Regrouping of Co-morbidities		
Diabetes Mellitus	Diabetes Mellitus	52 (48.1)
Hypothyroidism	Others	
Infection	Others	56 (51.9)
Autoimmune Disease	Others	
Nil	Others	
Regrouping of regimens		
PC	PC Regimen	15 (13.9)
Nab-PC	Other Carboplatin-Based Regimen	21 (19.4)
TCH	Other Carboplatin-Based Regimen	
CAPOX	Oxaliplatin-Based Regimen	
FLOT	Oxaliplatin-Based Regimen	36 (33.3)
FOLFIRINOX	Oxaliplatin-Based Regimen	
Cisplatin	Cisplatin-Based Regimen	36 (33.3)
BEP	Cisplatin-Based Regimen	

PC – Paclitaxel, Carboplatin; Nab-PC – Nab- Paclitaxel, Carboplatin; TCH: Docetaxel, Carboplatin, and 5-Fluorouracil; CAPOX: Capecitabine and Oxaliplatin; FLOT: 5-Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel; FOLFIRINOX: 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin; BEP: Bleomycin, Etoposide, and Cisplatin.